Antineoplastic treatment with crizotinib during pregnancy: a case report

Kristian H. Jensen; Gitte Persson; Lone Storgaard; Birgitte B. Nielsen; Berit W. Pedersen; Lisa L. Maroun; Alwin Huitema; Mette Pøhl

doi:10.1080/0284186X.2018.1497302

Antineoplastic treatment with crizotinib during pregnancy: a case report

Kristian H. Jensen^*, Gitte Persson, Lone Storgaard, Birgitte B. Nielsen, Berit W. Pedersen, Lisa L. Maroun, Alwin Huitema, Mette Pøhl

^*Corresponding author for this work

Research output: Contribution to journal › Letter › Research › peer-review

12 Citations (Scopus)

4 Downloads (Pure)

Abstract

The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [Citation1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

Original language	English
Journal	Acta Oncologica
Volume	58
Issue number	1
Pages (from-to)	121-122
Number of pages	2
ISSN	0284-186X
DOIs	https://doi.org/10.1080/0284186X.2018.1497302
Publication status	Published - 2019

Access to Document

10.1080/0284186X.2018.1497302

FulltextFinal published version, 959 KB

Cite this

@article{3cd1d4f07ff046eea7d37a1a8450e1d2,

title = "Antineoplastic treatment with crizotinib during pregnancy: a case report",

abstract = "The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [Citation1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.",

author = "Jensen, {Kristian H.} and Gitte Persson and Lone Storgaard and Nielsen, {Birgitte B.} and Pedersen, {Berit W.} and Maroun, {Lisa L.} and Alwin Huitema and Mette P{\o}hl",

year = "2019",

doi = "10.1080/0284186X.2018.1497302",

language = "English",

volume = "58",

pages = "121--122",

journal = "Acta Oncologica",

issn = "1100-1704",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Antineoplastic treatment with crizotinib during pregnancy

T2 - a case report

AU - Jensen, Kristian H.

AU - Persson, Gitte

AU - Storgaard, Lone

AU - Nielsen, Birgitte B.

AU - Pedersen, Berit W.

AU - Maroun, Lisa L.

AU - Huitema, Alwin

AU - Pøhl, Mette

PY - 2019

Y1 - 2019

N2 - The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [Citation1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

AB - The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [Citation1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

U2 - 10.1080/0284186X.2018.1497302

DO - 10.1080/0284186X.2018.1497302

M3 - Letter

C2 - 30101631

AN - SCOPUS:85061578145

VL - 58

SP - 121

EP - 122

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1100-1704

IS - 1

ER -